{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:25:52Z","timestamp":1789687552449,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Changsha Natural Science Foundation","award":["grant no. kq2004154"],"award-info":[{"award-number":["grant no. kq2004154"]}]},{"name":"Changsha Natural Science Foundation","award":["grant no. kq2004154"],"award-info":[{"award-number":["grant no. kq2004154"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Genom Data"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Previous research has already indicated an elevated risk of breast cancer (BC) among survivors of malignant lymphoma, but the underlying reasons remain unknown. Our objective is to elucidate the causal relationship between malignant lymphoma and BC through Mendelian randomization (MR). Genome-wide association studies (GWAS) data from 181,125 Hodgkin lymphoma (HL) patients and 181,289 non-Hodgkin lymphoma (NHL) patients from the FinnGen Consortium were utilized as exposure. We selected single nucleotide polymorphisms (SNPs) strongly associated with the exposure as instrumental variables to investigate their relationship with BC in a cohort of 107,722 participants. Subsequently, we obtained data from the UK Biobank containing gender-stratified information on HL, NHL, and BC. We validated the findings from our analysis and explored the impact of gender. The Inverse-Variance Weighted (IVW) method served as the primary reference for the two-sample MR, accompanied by tests for heterogeneity and pleiotropy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analysis results from the FinnGen consortium indicate that there is no causal relationship between HL and NHL with BC. HL (OR\u2009=\u20091.01, 95% CI\u2009=\u20090.98\u20131.04, p\u2009=\u20090.29), NHL (OR\u2009=\u20091.01, 95% CI\u2009=\u20090.96\u20131.05, p\u2009=\u20090.64). When utilizing GWAS data from the UK Biobank that includes different gender cohorts, the lack of association between HL, NHL, and BC remains consistent. HL (OR\u2009=\u20091.08, 95% CI\u2009=\u20090.74\u20131.56, p\u2009=\u20090.69), HL-Female (OR\u2009=\u20090.84, 95% CI\u2009=\u20090.59\u20131.19, p\u2009=\u20090.33), NHL (OR\u2009=\u20090.89, 95% CI\u2009=\u20090.66\u20131.19, p\u2009=\u20090.44), and NHL-Female (OR\u2009=\u20090.81, 95% CI\u2009=\u20090.58\u20131.11, p\u2009=\u20090.18).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The two-sample MR analysis indicates that there is no significant causal relationship between malignant lymphoma (HL and NHL) and BC. The association between malignant lymphoma and breast cancer requires further in-depth research and exploration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12863-023-01162-1","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T11:03:07Z","timestamp":1696849387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Correlation study of malignant lymphoma and breast Cancer in different gender European populations: mendelian randomization analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuoHuang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"1162_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.20134","volume":"61","author":"C DeSantis","year":"2011","unstructured":"DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409\u201318. https:\/\/doi.org\/10.3322\/caac.20134.","journal-title":"CA Cancer J Clin"},{"key":"1162_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66. https:\/\/doi.org\/10.1038\/s41572-019-0111-2.","journal-title":"Nat Rev Dis Primers"},{"key":"1162_CR3","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1001\/jama.286.17.2143","volume":"286","author":"KW Singletary","year":"2001","unstructured":"Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA. 2001;286:2143\u201351. https:\/\/doi.org\/10.1001\/jama.286.17.2143.","journal-title":"JAMA"},{"key":"1162_CR4","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/jnci\/djab053","volume":"113","author":"HS Feigelson","year":"2021","unstructured":"Feigelson HS, Bodelon C, Powers JD, et al. Body Mass Index and Risk of Second Cancer among women with breast Cancer. J Natl Cancer Inst. 2021;113:1156\u201360. https:\/\/doi.org\/10.1093\/jnci\/djab053.","journal-title":"J Natl Cancer Inst"},{"key":"1162_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12916-020-01797-2","volume":"18","author":"M Escala-Garcia","year":"2020","unstructured":"Escala-Garcia M, Morra A, Canisius S, et al. Breast cancer risk factors and their effects on survival: a mendelian randomisation study. BMC Med. 2020;18:327. https:\/\/doi.org\/10.1186\/s12916-020-01797-2.","journal-title":"BMC Med"},{"key":"1162_CR6","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1182\/blood-2018-07-862607","volume":"133","author":"AWJ Opstal-van Winden","year":"2019","unstructured":"Opstal-van Winden AWJ, de Haan HG, Hauptmann M, et al. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. Blood. 2019;133:1130\u20139. https:\/\/doi.org\/10.1182\/blood-2018-07-862607.","journal-title":"Blood"},{"key":"1162_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2011-10-383380","volume":"119","author":"YP Ma","year":"2012","unstructured":"Ma YP, van Leeuwen FE, Cooke R, et al. FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. Blood. 2012;119:1029\u201331. https:\/\/doi.org\/10.1182\/blood-2011-10-383380.","journal-title":"Blood"},{"key":"1162_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJM199603213341201","volume":"334","author":"S Bhatia","year":"1996","unstructured":"Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin\u2019s disease. N Engl J Med. 1996;334:745\u201351. https:\/\/doi.org\/10.1056\/NEJM199603213341201.","journal-title":"N Engl J Med"},{"key":"1162_CR9","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1200\/JCO.2013.54.4601","volume":"32","author":"CS Moskowitz","year":"2014","unstructured":"Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32:2217\u201323. https:\/\/doi.org\/10.1200\/JCO.2013.54.4601.","journal-title":"J Clin Oncol"},{"key":"1162_CR10","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","volume":"30","author":"AJ Swerdlow","year":"2012","unstructured":"Swerdlow AJ, Cooke R, Bates A, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a National Cohort Study. J Clin Oncol. 2012;30:2745\u201352. https:\/\/doi.org\/10.1200\/JCO.2011.38.8835.","journal-title":"J Clin Oncol"},{"key":"1162_CR11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/(sici)1097-0142(19970315)79:6%3C1203::aid-cncr20%3E3.0.co;2-2","volume":"79","author":"AC Aisenberg","year":"1997","unstructured":"Aisenberg AC, Finkelstein DM, Doppke KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin\u2019s disease. Cancer. 1997;79:1203\u201310. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19970315)79:6%3C1203::aid-cncr20%3E3.0.co;2-2.","journal-title":"Cancer"},{"key":"1162_CR12","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second Cancer Risk up to 40 years after treatment for Hodgkin\u2019s lymphoma. N Engl J Med. 2015;373:2499\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa1505949.","journal-title":"N Engl J Med"},{"key":"1162_CR13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/jnci\/djac125","volume":"114","author":"S Roberti","year":"2022","unstructured":"Roberti S, van Leeuwen FE, Ronckers CM, et al. Radiotherapy-Related dose and irradiated volume Effects on breast Cancer risk among Hodgkin Lymphoma Survivors. J Natl Cancer Inst. 2022;114:1270\u20138. https:\/\/doi.org\/10.1093\/jnci\/djac125.","journal-title":"J Natl Cancer Inst"},{"key":"1162_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.290.4.465","volume":"290","author":"LB Travis","year":"2003","unstructured":"Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465\u201375. https:\/\/doi.org\/10.1001\/jama.290.4.465.","journal-title":"JAMA"},{"key":"1162_CR15","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1200\/JCO.2009.22.9120","volume":"27","author":"M Crump","year":"2009","unstructured":"Crump M, Hodgson D. Secondary breast cancer in Hodgkin\u2019s lymphoma survivors. J Clin Oncol. 2009;27:4229\u201331. https:\/\/doi.org\/10.1200\/JCO.2009.22.9120.","journal-title":"J Clin Oncol"},{"key":"1162_CR16","doi-asserted-by":"publisher","unstructured":"de Vries S, Krul I, Schaapveld M, et al. Risk of male breast cancer after Hodgkin lymphoma. Blood Blood. 2023;2023020940. https:\/\/doi.org\/10.1182\/blood.2023020940.","DOI":"10.1182\/blood.2023020940"},{"key":"1162_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41408-021-00595-0","volume":"11","author":"D Kang","year":"2021","unstructured":"Kang D, Yoon SE, Shin D, et al. Risk of non-hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. Blood Cancer J. 2021;11:200. https:\/\/doi.org\/10.1038\/s41408-021-00595-0.","journal-title":"Blood Cancer J"},{"key":"1162_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.ajkd.2005.10.027","volume":"47","author":"C Zoccali","year":"2006","unstructured":"Zoccali C, Testa A, Spoto B, et al. Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis. 2006;47:332\u201341. https:\/\/doi.org\/10.1053\/j.ajkd.2005.10.027.","journal-title":"Am J Kidney Dis"},{"key":"1162_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"GD Smith","year":"2003","unstructured":"Smith GD, Ebrahim S. Mendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1\u201322. https:\/\/doi.org\/10.1093\/ije\/dyg070.","journal-title":"Int J Epidemiol"},{"key":"1162_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jrsm.1346","volume":"10","author":"J Bowden","year":"2019","unstructured":"Bowden J, Holmes MV. Meta-analysis and mendelian randomization: a review. Res Synth Methods. 2019;10:486\u201396. https:\/\/doi.org\/10.1002\/jrsm.1346.","journal-title":"Res Synth Methods"},{"key":"1162_CR21","doi-asserted-by":"publisher","first-page":"k601","DOI":"10.1136\/bmj.k601","volume":"362","author":"NM Davies","year":"2018","unstructured":"Davies NM, Holmes MV, Davey Smith G. Reading mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. https:\/\/doi.org\/10.1136\/bmj.k601.","journal-title":"BMJ"},{"key":"1162_CR22","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1681\/ASN.2016010098","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula P, Del Greco MF, Pattaro C, K\u00f6ttgen A. Mendelian randomization as an Approach to assess causality using Observational Data. J Am Soc Nephrol. 2016;27:3253\u201365. https:\/\/doi.org\/10.1681\/ASN.2016010098.","journal-title":"J Am Soc Nephrol"},{"key":"1162_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/ije\/dyv071","volume":"44","author":"AGC Boef","year":"2015","unstructured":"Boef AGC, Dekkers OM, le Cessie S. Mendelian randomization studies: a review of the approaches used and the quality of reporting. Int J Epidemiol. 2015;44:496\u2013511. https:\/\/doi.org\/10.1093\/ije\/dyv071.","journal-title":"Int J Epidemiol"},{"key":"1162_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","volume":"36","author":"AR Carter","year":"2021","unstructured":"Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36:465\u201378. https:\/\/doi.org\/10.1007\/s10654-021-00757-1.","journal-title":"Eur J Epidemiol"},{"key":"1162_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693\u20138. https:\/\/doi.org\/10.1038\/s41588-018-0099-7.","journal-title":"Nat Genet"},{"key":"1162_CR26","doi-asserted-by":"publisher","first-page":"k3788","DOI":"10.1136\/bmj.k3788","volume":"362","author":"RE Wootton","year":"2018","unstructured":"Wootton RE, Lawn RB, Millard LAC, et al. Evaluation of the causal effects between subjective wellbeing and cardiometabolic health: mendelian randomisation study. BMJ. 2018;362:k3788. https:\/\/doi.org\/10.1136\/bmj.k3788.","journal-title":"BMJ"},{"key":"1162_CR27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/ije\/dyq151","volume":"40","author":"BL Pierce","year":"2011","unstructured":"Pierce BL, Ahsan H, VanderWeele TJ. Power and instrument strength requirements for mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40:740\u201352. https:\/\/doi.org\/10.1093\/ije\/dyq151.","journal-title":"Int J Epidemiol"},{"key":"1162_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"1162_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512\u201325. https:\/\/doi.org\/10.1093\/ije\/dyv080.","journal-title":"Int J Epidemiol"},{"key":"1162_CR30","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1093\/bioinformatics\/btab665","volume":"37","author":"AE Murphy","year":"2021","unstructured":"Murphy AE, Schilder BM, Skene NG. MungeSumstats: a Bioconductor package for the standardization and quality control of many GWAS summary statistics. Bioinformatics. 2021;37:4593\u20136. https:\/\/doi.org\/10.1093\/bioinformatics\/btab665.","journal-title":"Bioinformatics"},{"key":"1162_CR31","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","volume":"21","author":"BMP Aleman","year":"2003","unstructured":"Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease. J Clin Oncol. 2003;21:3431\u20139. https:\/\/doi.org\/10.1200\/JCO.2003.07.131.","journal-title":"J Clin Oncol"},{"key":"1162_CR32","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/jnci\/dji290","volume":"97","author":"LB Travis","year":"2005","unstructured":"Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428\u201337. https:\/\/doi.org\/10.1093\/jnci\/dji290.","journal-title":"J Natl Cancer Inst"},{"key":"1162_CR33","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","volume":"20","author":"GM Dores","year":"2002","unstructured":"Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484\u201394. https:\/\/doi.org\/10.1200\/JCO.2002.09.038.","journal-title":"J Clin Oncol"},{"key":"1162_CR34","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/annonc\/mdl399","volume":"18","author":"G Sanna","year":"2007","unstructured":"Sanna G, Lorizzo K, Rotmensz N, et al. Breast cancer in Hodgkin\u2019s disease and non-hodgkin\u2019s lymphoma survivors. Ann Oncol. 2007;18:288\u201392. https:\/\/doi.org\/10.1093\/annonc\/mdl399.","journal-title":"Ann Oncol"},{"key":"1162_CR35","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s12094-022-03026-z","volume":"25","author":"X Lv","year":"2023","unstructured":"Lv X, Yue P, Zhou F. Risk and prognosis of secondary breast cancer after radiation therapy for non-hodgkin lymphoma: a massive population-based analysis. Clin Transl Oncol. 2023;25:1307\u201314. https:\/\/doi.org\/10.1007\/s12094-022-03026-z.","journal-title":"Clin Transl Oncol"},{"key":"1162_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/annonc\/7.suppl_4.s115","volume":"4","author":"M Henry-Amar","year":"1996","unstructured":"Henry-Amar M, Joly F. Late complications after Hodgkin\u2019s disease. Ann Oncol 7 Suppl. 1996;4:115\u201326. https:\/\/doi.org\/10.1093\/annonc\/7.suppl_4.s115.","journal-title":"Ann Oncol 7 Suppl"},{"key":"1162_CR37","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2008-10-184705","volume":"113","author":"ML De Bruin","year":"2009","unstructured":"De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood. 2009;113:3679\u201381. https:\/\/doi.org\/10.1182\/blood-2008-10-184705.","journal-title":"Blood"},{"key":"1162_CR38","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdu287","volume":"25","author":"GM Dores","year":"2014","unstructured":"Dores GM, Curtis RE, van Leeuwen FE, et al. Pancreatic cancer risk after treatment of Hodgkin lymphoma. Ann Oncol. 2014;25:2073\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdu287.","journal-title":"Ann Oncol"},{"key":"1162_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2013-10-532184","volume":"124","author":"AM van Eggermond","year":"2014","unstructured":"van Eggermond AM, Schaapveld M, Lugtenburg PJ, et al. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014;124:319\u201327. https:\/\/doi.org\/10.1182\/blood-2013-10-532184. quiz 466.","journal-title":"Blood"},{"key":"1162_CR40","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/1097-0142(19910401)67:7%3C2002::aid-cncr2820670729%3E3.0.co;2-e","volume":"67","author":"LB Travis","year":"1991","unstructured":"Travis LB, Curtis RE, Boice JD, et al. Second cancers following non-hodgkin\u2019s lymphoma. Cancer. 1991;67:2002\u20139. https:\/\/doi.org\/10.1002\/1097-0142(19910401)67:7%3C2002::aid-cncr2820670729%3E3.0.co;2-e.","journal-title":"Cancer"},{"key":"1162_CR41","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1054\/bjoc.1999.1102","volume":"82","author":"P Brennan","year":"2000","unstructured":"Brennan P, Coates M, Armstrong B, et al. Second primary neoplasms following non-hodgkin\u2019s lymphoma in New South Wales, Australia. Br J Cancer. 2000;82:1344\u20137. https:\/\/doi.org\/10.1054\/bjoc.1999.1102.","journal-title":"Br J Cancer"},{"key":"1162_CR42","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","volume":"24","author":"NY Mudie","year":"2006","unstructured":"Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-hodgkin\u2019s lymphoma: a british Cohort Study. J Clin Oncol. 2006;24:1568\u201374. https:\/\/doi.org\/10.1200\/JCO.2005.04.2200.","journal-title":"J Clin Oncol"}],"container-title":["BMC Genomic Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12863-023-01162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12863-023-01162-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12863-023-01162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:12:35Z","timestamp":1700266355000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgenet.biomedcentral.com\/articles\/10.1186\/s12863-023-01162-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1186\/s12863-023-01162-1","relation":{},"ISSN":["2730-6844"],"issn-type":[{"value":"2730-6844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"14 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data available in this study are from public databases with no ethical and copyright issues.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}